Header image for  Pareto Securities’ 11th Annual Healthcare Conference
Profile image for Nordic Nanovector

Nordic Nanovector Exhibitor

Type of industry

Biotech

Presentation
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Presentations

Nordic Nanovector

Thursday September 3, 2020 15:00 - 15:30 CEST Room 2

Representatives

Lars Nieba SpeakerExhibitor

Interim CEO
Nordic Nanovector

Kristina Håbjørg Exhibitor

Nordic Nanovector